星空体育官方入口网站网址大全-登录入口官网

[GetPortalCommentsPageByObjectIdResponse(id=573740, encodeId=a5695e3740d1, content=需要提供原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74ea2533295, createdName=12507549m42(暂无昵称), createdTime=Wed Jul 17 10:52:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009731, encodeId=293d1009e3161, content=审稿速度:2.0 偏重的研究方向：肿瘤药 经验分享：投稿一个月了一点消息也没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ad85410909, createdName=ms1000000471935050, createdTime=Fri Aug 20 14:42:19 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948982, encodeId=3c1394898255, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：投的一篇靶向药物的综述，一审一个月，编辑给的大修，两个审稿人意见中肯，按照要求新作了两个figure，完善了table，二审两个月后接收。过程坎坷，感谢。 投稿难度中等，总时间大概在半年以内，毕业的同学可以考虑一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deed5470088, createdName=ms5000001940143695, createdTime=Wed Mar 17 14:10:33 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109435, encodeId=93ee21094359c, content=临床研究接收吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75378229123, createdName=ms8000000480742952, createdTime=Sun Jan 08 21:46:12 CST 2023, time=2023-01-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2109436, encodeId=8c672109436c7, content=请问临床试验的文章接受吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75378229123, createdName=ms8000000480742952, createdTime=Sun Jan 08 21:48:21 CST 2023, time=2023-01-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2097923, encodeId=314a209e92391, content=偏重的研究方向：药物靶点 经验分享：2022年7月20日投稿 2022年9月7日返回意见两个审稿人意见较为中肯编辑给了reject&resubmit 按照审稿意见进行修改后重新投到该杂志 9月27日投稿 11月1日返回意见仅有一个审稿人该审稿人审稿极不负责仅以创新性不足建议拒绝该审稿人认为创新性不足的原因是依旧有过药物对某靶点的研究对本文重点探讨的某病理生理过程只字不提且在后面对我们药物的使用方式提出了质疑（溶液还是其他方式）我们在实验方法中已经明确写出使用方法与我们之前实验中的用法相同已经在之前的文章中阐释过总之就是该审稿人水平较差已经打算写邮件给编辑吐槽该审稿人<a href='/topic/show?id=f6ec5618380' target=_blank style='color:#2F92EE;'>#拒稿#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=56183, encryptionId=f6ec5618380, topicName=拒稿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02075542342, createdName=ms1000001180103395, createdTime=Tue Nov 01 20:21:20 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092957, encodeId=dd1f109295e5f, content=什么是协同作用？什么是相加作用？两者有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092958, encodeId=ae12109295828, content=一般期刊要求几张图/几个表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585632, encodeId=c4c3585632b0, content=不用133okyg0842(暂无昵称) 2019-07-17 10:52:00 发表: 需要提供原始数据吗？, beContent=133okyg0842(暂无昵称) 2019-07-17 10:52:00 发表: 需要提供原始数据吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e015108382, createdName=1460c6cbm53(暂无昵称), createdTime=Sun Mar 01 00:00:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539386, encodeId=30a0539386ab, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=)]

2019-07-17 12507549m42(暂无昵称)

需要提供原始数据吗？

195 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=573740, encodeId=a5695e3740d1, content=需要提供原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74ea2533295, createdName=12507549m42(暂无昵称), createdTime=Wed Jul 17 10:52:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009731, encodeId=293d1009e3161, content=审稿速度:2.0 偏重的研究方向：肿瘤药 经验分享：投稿一个月了一点消息也没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ad85410909, createdName=ms1000000471935050, createdTime=Fri Aug 20 14:42:19 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948982, encodeId=3c1394898255, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：投的一篇靶向药物的综述，一审一个月，编辑给的大修，两个审稿人意见中肯，按照要求新作了两个figure，完善了table，二审两个月后接收。过程坎坷，感谢。 投稿难度中等，总时间大概在半年以内，毕业的同学可以考虑一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deed5470088, createdName=ms5000001940143695, createdTime=Wed Mar 17 14:10:33 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109435, encodeId=93ee21094359c, content=临床研究接收吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75378229123, createdName=ms8000000480742952, createdTime=Sun Jan 08 21:46:12 CST 2023, time=2023-01-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2109436, encodeId=8c672109436c7, content=请问临床试验的文章接受吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75378229123, createdName=ms8000000480742952, createdTime=Sun Jan 08 21:48:21 CST 2023, time=2023-01-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2097923, encodeId=314a209e92391, content=偏重的研究方向：药物靶点 经验分享：2022年7月20日投稿 2022年9月7日返回意见两个审稿人意见较为中肯编辑给了reject&resubmit 按照审稿意见进行修改后重新投到该杂志 9月27日投稿 11月1日返回意见仅有一个审稿人该审稿人审稿极不负责仅以创新性不足建议拒绝该审稿人认为创新性不足的原因是依旧有过药物对某靶点的研究对本文重点探讨的某病理生理过程只字不提且在后面对我们药物的使用方式提出了质疑（溶液还是其他方式）我们在实验方法中已经明确写出使用方法与我们之前实验中的用法相同已经在之前的文章中阐释过总之就是该审稿人水平较差已经打算写邮件给编辑吐槽该审稿人<a href='/topic/show?id=f6ec5618380' target=_blank style='color:#2F92EE;'>#拒稿#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=56183, encryptionId=f6ec5618380, topicName=拒稿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02075542342, createdName=ms1000001180103395, createdTime=Tue Nov 01 20:21:20 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092957, encodeId=dd1f109295e5f, content=什么是协同作用？什么是相加作用？两者有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092958, encodeId=ae12109295828, content=一般期刊要求几张图/几个表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585632, encodeId=c4c3585632b0, content=不用133okyg0842(暂无昵称) 2019-07-17 10:52:00 发表: 需要提供原始数据吗？, beContent=133okyg0842(暂无昵称) 2019-07-17 10:52:00 发表: 需要提供原始数据吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e015108382, createdName=1460c6cbm53(暂无昵称), createdTime=Sun Mar 01 00:00:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539386, encodeId=30a0539386ab, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=)]

2021-08-20 ms1000000471935050

审稿速度:2.0
偏重的研究方向：肿瘤药
经验分享：投稿一个月了一点消息也没有

76 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=573740, encodeId=a5695e3740d1, content=需要提供原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74ea2533295, createdName=12507549m42(暂无昵称), createdTime=Wed Jul 17 10:52:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009731, encodeId=293d1009e3161, content=审稿速度:2.0 偏重的研究方向：肿瘤药 经验分享：投稿一个月了一点消息也没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ad85410909, createdName=ms1000000471935050, createdTime=Fri Aug 20 14:42:19 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948982, encodeId=3c1394898255, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：投的一篇靶向药物的综述，一审一个月，编辑给的大修，两个审稿人意见中肯，按照要求新作了两个figure，完善了table，二审两个月后接收。过程坎坷，感谢。 投稿难度中等，总时间大概在半年以内，毕业的同学可以考虑一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deed5470088, createdName=ms5000001940143695, createdTime=Wed Mar 17 14:10:33 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109435, encodeId=93ee21094359c, content=临床研究接收吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75378229123, createdName=ms8000000480742952, createdTime=Sun Jan 08 21:46:12 CST 2023, time=2023-01-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2109436, encodeId=8c672109436c7, content=请问临床试验的文章接受吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75378229123, createdName=ms8000000480742952, createdTime=Sun Jan 08 21:48:21 CST 2023, time=2023-01-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2097923, encodeId=314a209e92391, content=偏重的研究方向：药物靶点 经验分享：2022年7月20日投稿 2022年9月7日返回意见两个审稿人意见较为中肯编辑给了reject&resubmit 按照审稿意见进行修改后重新投到该杂志 9月27日投稿 11月1日返回意见仅有一个审稿人该审稿人审稿极不负责仅以创新性不足建议拒绝该审稿人认为创新性不足的原因是依旧有过药物对某靶点的研究对本文重点探讨的某病理生理过程只字不提且在后面对我们药物的使用方式提出了质疑（溶液还是其他方式）我们在实验方法中已经明确写出使用方法与我们之前实验中的用法相同已经在之前的文章中阐释过总之就是该审稿人水平较差已经打算写邮件给编辑吐槽该审稿人<a href='/topic/show?id=f6ec5618380' target=_blank style='color:#2F92EE;'>#拒稿#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=56183, encryptionId=f6ec5618380, topicName=拒稿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02075542342, createdName=ms1000001180103395, createdTime=Tue Nov 01 20:21:20 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092957, encodeId=dd1f109295e5f, content=什么是协同作用？什么是相加作用？两者有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092958, encodeId=ae12109295828, content=一般期刊要求几张图/几个表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585632, encodeId=c4c3585632b0, content=不用133okyg0842(暂无昵称) 2019-07-17 10:52:00 发表: 需要提供原始数据吗？, beContent=133okyg0842(暂无昵称) 2019-07-17 10:52:00 发表: 需要提供原始数据吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e015108382, createdName=1460c6cbm53(暂无昵称), createdTime=Sun Mar 01 00:00:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539386, encodeId=30a0539386ab, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=)]

2021-03-17 ms5000001940143695

审稿速度:6.0 | 投稿命中率:50.0
经验分享：投的一篇靶向药物的综述，一审一个月，编辑给的大修，两个审稿人意见中肯，按照要求新作了两个figure，完善了table，二审两个月后接收。过程坎坷，感谢。
投稿难度中等，总时间大概在半年以内，毕业的同学可以考虑一下

96 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=573740, encodeId=a5695e3740d1, content=需要提供原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74ea2533295, createdName=12507549m42(暂无昵称), createdTime=Wed Jul 17 10:52:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009731, encodeId=293d1009e3161, content=审稿速度:2.0 偏重的研究方向：肿瘤药 经验分享：投稿一个月了一点消息也没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ad85410909, createdName=ms1000000471935050, createdTime=Fri Aug 20 14:42:19 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948982, encodeId=3c1394898255, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：投的一篇靶向药物的综述，一审一个月，编辑给的大修，两个审稿人意见中肯，按照要求新作了两个figure，完善了table，二审两个月后接收。过程坎坷，感谢。 投稿难度中等，总时间大概在半年以内，毕业的同学可以考虑一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deed5470088, createdName=ms5000001940143695, createdTime=Wed Mar 17 14:10:33 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109435, encodeId=93ee21094359c, content=临床研究接收吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75378229123, createdName=ms8000000480742952, createdTime=Sun Jan 08 21:46:12 CST 2023, time=2023-01-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2109436, encodeId=8c672109436c7, content=请问临床试验的文章接受吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75378229123, createdName=ms8000000480742952, createdTime=Sun Jan 08 21:48:21 CST 2023, time=2023-01-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2097923, encodeId=314a209e92391, content=偏重的研究方向：药物靶点 经验分享：2022年7月20日投稿 2022年9月7日返回意见两个审稿人意见较为中肯编辑给了reject&resubmit 按照审稿意见进行修改后重新投到该杂志 9月27日投稿 11月1日返回意见仅有一个审稿人该审稿人审稿极不负责仅以创新性不足建议拒绝该审稿人认为创新性不足的原因是依旧有过药物对某靶点的研究对本文重点探讨的某病理生理过程只字不提且在后面对我们药物的使用方式提出了质疑（溶液还是其他方式）我们在实验方法中已经明确写出使用方法与我们之前实验中的用法相同已经在之前的文章中阐释过总之就是该审稿人水平较差已经打算写邮件给编辑吐槽该审稿人<a href='/topic/show?id=f6ec5618380' target=_blank style='color:#2F92EE;'>#拒稿#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=56183, encryptionId=f6ec5618380, topicName=拒稿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02075542342, createdName=ms1000001180103395, createdTime=Tue Nov 01 20:21:20 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092957, encodeId=dd1f109295e5f, content=什么是协同作用？什么是相加作用？两者有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092958, encodeId=ae12109295828, content=一般期刊要求几张图/几个表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585632, encodeId=c4c3585632b0, content=不用133okyg0842(暂无昵称) 2019-07-17 10:52:00 发表: 需要提供原始数据吗？, beContent=133okyg0842(暂无昵称) 2019-07-17 10:52:00 发表: 需要提供原始数据吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e015108382, createdName=1460c6cbm53(暂无昵称), createdTime=Sun Mar 01 00:00:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539386, encodeId=30a0539386ab, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=)]

2023-01-08 ms8000000480742952 来自上海

临床研究接收吗？

66 0

[GetPortalCommentsPageByObjectIdResponse(id=573740, encodeId=a5695e3740d1, content=需要提供原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74ea2533295, createdName=12507549m42(暂无昵称), createdTime=Wed Jul 17 10:52:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009731, encodeId=293d1009e3161, content=审稿速度:2.0 偏重的研究方向：肿瘤药 经验分享：投稿一个月了一点消息也没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ad85410909, createdName=ms1000000471935050, createdTime=Fri Aug 20 14:42:19 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948982, encodeId=3c1394898255, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：投的一篇靶向药物的综述，一审一个月，编辑给的大修，两个审稿人意见中肯，按照要求新作了两个figure，完善了table，二审两个月后接收。过程坎坷，感谢。 投稿难度中等，总时间大概在半年以内，毕业的同学可以考虑一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deed5470088, createdName=ms5000001940143695, createdTime=Wed Mar 17 14:10:33 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109435, encodeId=93ee21094359c, content=临床研究接收吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75378229123, createdName=ms8000000480742952, createdTime=Sun Jan 08 21:46:12 CST 2023, time=2023-01-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2109436, encodeId=8c672109436c7, content=请问临床试验的文章接受吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75378229123, createdName=ms8000000480742952, createdTime=Sun Jan 08 21:48:21 CST 2023, time=2023-01-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2097923, encodeId=314a209e92391, content=偏重的研究方向：药物靶点 经验分享：2022年7月20日投稿 2022年9月7日返回意见两个审稿人意见较为中肯编辑给了reject&resubmit 按照审稿意见进行修改后重新投到该杂志 9月27日投稿 11月1日返回意见仅有一个审稿人该审稿人审稿极不负责仅以创新性不足建议拒绝该审稿人认为创新性不足的原因是依旧有过药物对某靶点的研究对本文重点探讨的某病理生理过程只字不提且在后面对我们药物的使用方式提出了质疑（溶液还是其他方式）我们在实验方法中已经明确写出使用方法与我们之前实验中的用法相同已经在之前的文章中阐释过总之就是该审稿人水平较差已经打算写邮件给编辑吐槽该审稿人<a href='/topic/show?id=f6ec5618380' target=_blank style='color:#2F92EE;'>#拒稿#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=56183, encryptionId=f6ec5618380, topicName=拒稿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02075542342, createdName=ms1000001180103395, createdTime=Tue Nov 01 20:21:20 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092957, encodeId=dd1f109295e5f, content=什么是协同作用？什么是相加作用？两者有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092958, encodeId=ae12109295828, content=一般期刊要求几张图/几个表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585632, encodeId=c4c3585632b0, content=不用133okyg0842(暂无昵称) 2019-07-17 10:52:00 发表: 需要提供原始数据吗？, beContent=133okyg0842(暂无昵称) 2019-07-17 10:52:00 发表: 需要提供原始数据吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e015108382, createdName=1460c6cbm53(暂无昵称), createdTime=Sun Mar 01 00:00:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539386, encodeId=30a0539386ab, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=)]

2023-01-08 ms8000000480742952 来自上海

请问临床试验的文章接受吗？

49 0

[GetPortalCommentsPageByObjectIdResponse(id=573740, encodeId=a5695e3740d1, content=需要提供原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74ea2533295, createdName=12507549m42(暂无昵称), createdTime=Wed Jul 17 10:52:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009731, encodeId=293d1009e3161, content=审稿速度:2.0 偏重的研究方向：肿瘤药 经验分享：投稿一个月了一点消息也没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ad85410909, createdName=ms1000000471935050, createdTime=Fri Aug 20 14:42:19 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948982, encodeId=3c1394898255, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：投的一篇靶向药物的综述，一审一个月，编辑给的大修，两个审稿人意见中肯，按照要求新作了两个figure，完善了table，二审两个月后接收。过程坎坷，感谢。 投稿难度中等，总时间大概在半年以内，毕业的同学可以考虑一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deed5470088, createdName=ms5000001940143695, createdTime=Wed Mar 17 14:10:33 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109435, encodeId=93ee21094359c, content=临床研究接收吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75378229123, createdName=ms8000000480742952, createdTime=Sun Jan 08 21:46:12 CST 2023, time=2023-01-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2109436, encodeId=8c672109436c7, content=请问临床试验的文章接受吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75378229123, createdName=ms8000000480742952, createdTime=Sun Jan 08 21:48:21 CST 2023, time=2023-01-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2097923, encodeId=314a209e92391, content=偏重的研究方向：药物靶点 经验分享：2022年7月20日投稿 2022年9月7日返回意见两个审稿人意见较为中肯编辑给了reject&resubmit 按照审稿意见进行修改后重新投到该杂志 9月27日投稿 11月1日返回意见仅有一个审稿人该审稿人审稿极不负责仅以创新性不足建议拒绝该审稿人认为创新性不足的原因是依旧有过药物对某靶点的研究对本文重点探讨的某病理生理过程只字不提且在后面对我们药物的使用方式提出了质疑（溶液还是其他方式）我们在实验方法中已经明确写出使用方法与我们之前实验中的用法相同已经在之前的文章中阐释过总之就是该审稿人水平较差已经打算写邮件给编辑吐槽该审稿人<a href='/topic/show?id=f6ec5618380' target=_blank style='color:#2F92EE;'>#拒稿#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=56183, encryptionId=f6ec5618380, topicName=拒稿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02075542342, createdName=ms1000001180103395, createdTime=Tue Nov 01 20:21:20 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092957, encodeId=dd1f109295e5f, content=什么是协同作用？什么是相加作用？两者有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092958, encodeId=ae12109295828, content=一般期刊要求几张图/几个表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585632, encodeId=c4c3585632b0, content=不用133okyg0842(暂无昵称) 2019-07-17 10:52:00 发表: 需要提供原始数据吗？, beContent=133okyg0842(暂无昵称) 2019-07-17 10:52:00 发表: 需要提供原始数据吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e015108382, createdName=1460c6cbm53(暂无昵称), createdTime=Sun Mar 01 00:00:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539386, encodeId=30a0539386ab, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=)]

2022-11-01 ms1000001180103395

偏重的研究方向：药物靶点
经验分享：2022年7月20日投稿 2022年9月7日返回意见两个审稿人意见较为中肯编辑给了reject&resubmit 按照审稿意见进行修改后重新投到该杂志 9月27日投稿 11月1日返回意见仅有一个审稿人该审稿人审稿极不负责仅以创新性不足建议拒绝该审稿人认为创新性不足的原因是依旧有过药物对某靶点的研究对本文重点探讨的某病理生理过程只字不提且在后面对我们药物的使用方式提出了质疑（溶液还是其他方式）我们在实验方法中已经明确写出使用方法与我们之前实验中的用法相同已经在之前的文章中阐释过总之就是该审稿人水平较差已经打算写邮件给编辑吐槽该审稿人#拒稿#

64 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=573740, encodeId=a5695e3740d1, content=需要提供原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74ea2533295, createdName=12507549m42(暂无昵称), createdTime=Wed Jul 17 10:52:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009731, encodeId=293d1009e3161, content=审稿速度:2.0 偏重的研究方向：肿瘤药 经验分享：投稿一个月了一点消息也没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ad85410909, createdName=ms1000000471935050, createdTime=Fri Aug 20 14:42:19 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948982, encodeId=3c1394898255, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：投的一篇靶向药物的综述，一审一个月，编辑给的大修，两个审稿人意见中肯，按照要求新作了两个figure，完善了table，二审两个月后接收。过程坎坷，感谢。 投稿难度中等，总时间大概在半年以内，毕业的同学可以考虑一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deed5470088, createdName=ms5000001940143695, createdTime=Wed Mar 17 14:10:33 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109435, encodeId=93ee21094359c, content=临床研究接收吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75378229123, createdName=ms8000000480742952, createdTime=Sun Jan 08 21:46:12 CST 2023, time=2023-01-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2109436, encodeId=8c672109436c7, content=请问临床试验的文章接受吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75378229123, createdName=ms8000000480742952, createdTime=Sun Jan 08 21:48:21 CST 2023, time=2023-01-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2097923, encodeId=314a209e92391, content=偏重的研究方向：药物靶点 经验分享：2022年7月20日投稿 2022年9月7日返回意见两个审稿人意见较为中肯编辑给了reject&resubmit 按照审稿意见进行修改后重新投到该杂志 9月27日投稿 11月1日返回意见仅有一个审稿人该审稿人审稿极不负责仅以创新性不足建议拒绝该审稿人认为创新性不足的原因是依旧有过药物对某靶点的研究对本文重点探讨的某病理生理过程只字不提且在后面对我们药物的使用方式提出了质疑（溶液还是其他方式）我们在实验方法中已经明确写出使用方法与我们之前实验中的用法相同已经在之前的文章中阐释过总之就是该审稿人水平较差已经打算写邮件给编辑吐槽该审稿人<a href='/topic/show?id=f6ec5618380' target=_blank style='color:#2F92EE;'>#拒稿#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=56183, encryptionId=f6ec5618380, topicName=拒稿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02075542342, createdName=ms1000001180103395, createdTime=Tue Nov 01 20:21:20 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092957, encodeId=dd1f109295e5f, content=什么是协同作用？什么是相加作用？两者有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092958, encodeId=ae12109295828, content=一般期刊要求几张图/几个表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585632, encodeId=c4c3585632b0, content=不用133okyg0842(暂无昵称) 2019-07-17 10:52:00 发表: 需要提供原始数据吗？, beContent=133okyg0842(暂无昵称) 2019-07-17 10:52:00 发表: 需要提供原始数据吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e015108382, createdName=1460c6cbm53(暂无昵称), createdTime=Sun Mar 01 00:00:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539386, encodeId=30a0539386ab, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=)]

2021-12-27 小动量

什么是协同作用？什么是相加作用？两者有什么区别？

59 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=573740, encodeId=a5695e3740d1, content=需要提供原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74ea2533295, createdName=12507549m42(暂无昵称), createdTime=Wed Jul 17 10:52:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009731, encodeId=293d1009e3161, content=审稿速度:2.0 偏重的研究方向：肿瘤药 经验分享：投稿一个月了一点消息也没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ad85410909, createdName=ms1000000471935050, createdTime=Fri Aug 20 14:42:19 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948982, encodeId=3c1394898255, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：投的一篇靶向药物的综述，一审一个月，编辑给的大修，两个审稿人意见中肯，按照要求新作了两个figure，完善了table，二审两个月后接收。过程坎坷，感谢。 投稿难度中等，总时间大概在半年以内，毕业的同学可以考虑一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deed5470088, createdName=ms5000001940143695, createdTime=Wed Mar 17 14:10:33 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109435, encodeId=93ee21094359c, content=临床研究接收吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75378229123, createdName=ms8000000480742952, createdTime=Sun Jan 08 21:46:12 CST 2023, time=2023-01-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2109436, encodeId=8c672109436c7, content=请问临床试验的文章接受吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75378229123, createdName=ms8000000480742952, createdTime=Sun Jan 08 21:48:21 CST 2023, time=2023-01-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2097923, encodeId=314a209e92391, content=偏重的研究方向：药物靶点 经验分享：2022年7月20日投稿 2022年9月7日返回意见两个审稿人意见较为中肯编辑给了reject&resubmit 按照审稿意见进行修改后重新投到该杂志 9月27日投稿 11月1日返回意见仅有一个审稿人该审稿人审稿极不负责仅以创新性不足建议拒绝该审稿人认为创新性不足的原因是依旧有过药物对某靶点的研究对本文重点探讨的某病理生理过程只字不提且在后面对我们药物的使用方式提出了质疑（溶液还是其他方式）我们在实验方法中已经明确写出使用方法与我们之前实验中的用法相同已经在之前的文章中阐释过总之就是该审稿人水平较差已经打算写邮件给编辑吐槽该审稿人<a href='/topic/show?id=f6ec5618380' target=_blank style='color:#2F92EE;'>#拒稿#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=56183, encryptionId=f6ec5618380, topicName=拒稿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02075542342, createdName=ms1000001180103395, createdTime=Tue Nov 01 20:21:20 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092957, encodeId=dd1f109295e5f, content=什么是协同作用？什么是相加作用？两者有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092958, encodeId=ae12109295828, content=一般期刊要求几张图/几个表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585632, encodeId=c4c3585632b0, content=不用133okyg0842(暂无昵称) 2019-07-17 10:52:00 发表: 需要提供原始数据吗？, beContent=133okyg0842(暂无昵称) 2019-07-17 10:52:00 发表: 需要提供原始数据吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e015108382, createdName=1460c6cbm53(暂无昵称), createdTime=Sun Mar 01 00:00:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539386, encodeId=30a0539386ab, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=)]

2021-12-27 msSSSSSD

一般期刊要求几张图/几个表？

61 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=573740, encodeId=a5695e3740d1, content=需要提供原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74ea2533295, createdName=12507549m42(暂无昵称), createdTime=Wed Jul 17 10:52:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009731, encodeId=293d1009e3161, content=审稿速度:2.0 偏重的研究方向：肿瘤药 经验分享：投稿一个月了一点消息也没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ad85410909, createdName=ms1000000471935050, createdTime=Fri Aug 20 14:42:19 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948982, encodeId=3c1394898255, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：投的一篇靶向药物的综述，一审一个月，编辑给的大修，两个审稿人意见中肯，按照要求新作了两个figure，完善了table，二审两个月后接收。过程坎坷，感谢。 投稿难度中等，总时间大概在半年以内，毕业的同学可以考虑一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deed5470088, createdName=ms5000001940143695, createdTime=Wed Mar 17 14:10:33 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109435, encodeId=93ee21094359c, content=临床研究接收吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75378229123, createdName=ms8000000480742952, createdTime=Sun Jan 08 21:46:12 CST 2023, time=2023-01-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2109436, encodeId=8c672109436c7, content=请问临床试验的文章接受吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75378229123, createdName=ms8000000480742952, createdTime=Sun Jan 08 21:48:21 CST 2023, time=2023-01-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2097923, encodeId=314a209e92391, content=偏重的研究方向：药物靶点 经验分享：2022年7月20日投稿 2022年9月7日返回意见两个审稿人意见较为中肯编辑给了reject&resubmit 按照审稿意见进行修改后重新投到该杂志 9月27日投稿 11月1日返回意见仅有一个审稿人该审稿人审稿极不负责仅以创新性不足建议拒绝该审稿人认为创新性不足的原因是依旧有过药物对某靶点的研究对本文重点探讨的某病理生理过程只字不提且在后面对我们药物的使用方式提出了质疑（溶液还是其他方式）我们在实验方法中已经明确写出使用方法与我们之前实验中的用法相同已经在之前的文章中阐释过总之就是该审稿人水平较差已经打算写邮件给编辑吐槽该审稿人<a href='/topic/show?id=f6ec5618380' target=_blank style='color:#2F92EE;'>#拒稿#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=56183, encryptionId=f6ec5618380, topicName=拒稿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02075542342, createdName=ms1000001180103395, createdTime=Tue Nov 01 20:21:20 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092957, encodeId=dd1f109295e5f, content=什么是协同作用？什么是相加作用？两者有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092958, encodeId=ae12109295828, content=一般期刊要求几张图/几个表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585632, encodeId=c4c3585632b0, content=不用133okyg0842(暂无昵称) 2019-07-17 10:52:00 发表: 需要提供原始数据吗？, beContent=133okyg0842(暂无昵称) 2019-07-17 10:52:00 发表: 需要提供原始数据吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e015108382, createdName=1460c6cbm53(暂无昵称), createdTime=Sun Mar 01 00:00:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539386, encodeId=30a0539386ab, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=)]

2020-03-01 1460c6cbm53(暂无昵称)

不用133okyg0842(暂无昵称) 2019-07-17 10:52:00 发表:
需要提供原始数据吗？

133okyg0842(暂无昵称) 2019-07-17 10:52:00 发表: 需要提供原始数据吗？

164 0

[GetPortalCommentsPageByObjectIdResponse(id=573740, encodeId=a5695e3740d1, content=需要提供原始数据吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=195, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=74ea2533295, createdName=12507549m42(暂无昵称), createdTime=Wed Jul 17 10:52:00 CST 2019, time=2019-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1009731, encodeId=293d1009e3161, content=审稿速度:2.0 偏重的研究方向：肿瘤药 经验分享：投稿一个月了一点消息也没有, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4ad85410909, createdName=ms1000000471935050, createdTime=Fri Aug 20 14:42:19 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948982, encodeId=3c1394898255, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：投的一篇靶向药物的综述，一审一个月，编辑给的大修，两个审稿人意见中肯，按照要求新作了两个figure，完善了table，二审两个月后接收。过程坎坷，感谢。 投稿难度中等，总时间大概在半年以内，毕业的同学可以考虑一下, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deed5470088, createdName=ms5000001940143695, createdTime=Wed Mar 17 14:10:33 CST 2021, time=2021-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109435, encodeId=93ee21094359c, content=临床研究接收吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75378229123, createdName=ms8000000480742952, createdTime=Sun Jan 08 21:46:12 CST 2023, time=2023-01-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2109436, encodeId=8c672109436c7, content=请问临床试验的文章接受吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75378229123, createdName=ms8000000480742952, createdTime=Sun Jan 08 21:48:21 CST 2023, time=2023-01-08, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2097923, encodeId=314a209e92391, content=偏重的研究方向：药物靶点 经验分享：2022年7月20日投稿 2022年9月7日返回意见两个审稿人意见较为中肯编辑给了reject&resubmit 按照审稿意见进行修改后重新投到该杂志 9月27日投稿 11月1日返回意见仅有一个审稿人该审稿人审稿极不负责仅以创新性不足建议拒绝该审稿人认为创新性不足的原因是依旧有过药物对某靶点的研究对本文重点探讨的某病理生理过程只字不提且在后面对我们药物的使用方式提出了质疑（溶液还是其他方式）我们在实验方法中已经明确写出使用方法与我们之前实验中的用法相同已经在之前的文章中阐释过总之就是该审稿人水平较差已经打算写邮件给编辑吐槽该审稿人<a href='/topic/show?id=f6ec5618380' target=_blank style='color:#2F92EE;'>#拒稿#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=64, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=56183, encryptionId=f6ec5618380, topicName=拒稿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=02075542342, createdName=ms1000001180103395, createdTime=Tue Nov 01 20:21:20 CST 2022, time=2022-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092957, encodeId=dd1f109295e5f, content=什么是协同作用？什么是相加作用？两者有什么区别？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1092958, encodeId=ae12109295828, content=一般期刊要求几张图/几个表？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=msSSSSSD, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=585632, encodeId=c4c3585632b0, content=不用133okyg0842(暂无昵称) 2019-07-17 10:52:00 发表: 需要提供原始数据吗？, beContent=133okyg0842(暂无昵称) 2019-07-17 10:52:00 发表: 需要提供原始数据吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e015108382, createdName=1460c6cbm53(暂无昵称), createdTime=Sun Mar 01 00:00:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=539386, encodeId=30a0539386ab, content=3分边缘，希望能维持稳定，略有上升也不错。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=302, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=chenyuming, createdTime=Tue Jul 18 18:29:00 CST 2017, time=2017-07-18, status=1, ipAttribution=)]

2017-07-18 chenyuming

3分边缘，希望能维持稳定，略有上升也不错。

302 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务